Momenta Pharmaceuticals (Nasdaq: MNTA) saw its stock rise more than 5 percent on news that UBS AG equity analysts had initiated coverage on the stock. This despite the fact that the Swiss bank issued an initial Neutral rating with a one …
Wheeler. For a complete fundamental analysis analysis of Momenta Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for MNTA.
Spike
Including an estimated cash burn of $14M for 4Q08 + $95M cash reported at end 3Q08 + net proceeds of about $24M from mid-December sale of 2.8M shares of common stock at 9 bucks; MNTA enters 2009 with $105M in cash, about 9M in …
With its revolutionary inhalant and partnership with Sanofi, MannKind stock should hit its price target of $6. Momenta Pharmaceuticals Inc. Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) uses proprietary methods to construct and …
Biotechnology
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) is soaring today on the news that patents owned by the generic drug maker’s competition were struck down by a US district court. At the time of writing, shares of the pharmaceutical …
United States district court
The stock has climbed 55 percent in the last 12 months. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MNTA
CNBC21d
143 investment managers owned shares of Momenta Pharmaceuticals Inc. Our tracked institutional players have historically had a high interest in this company, and that was also the case in Q4 2014. The institutional ownership was …
POINT ROBERTS, October 31, 2011 - www.InvestorIdeas.com, a global investor research portal for independent …
Today, Aegis raised its price target on Momenta Pharmaceuticals (NASDAQ:MNTA) to per share. There are 1 sell rating, 3 hold ratings, 5 buy ratings on the stock. The current consensus rating on Momenta Pharmaceuticals …
Barclays sees a compelling risk/reward in Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) citing the Copaxone 40mg trial. The firm sees little risk in owning the stock pointing out successful IPR decisions, although no one could …